Cargando…

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence. Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control;...

Descripción completa

Detalles Bibliográficos
Autores principales: Polonsky, William H, Henry, Robert R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966497/
https://www.ncbi.nlm.nih.gov/pubmed/27524885
http://dx.doi.org/10.2147/PPA.S106821
_version_ 1782445390878998528
author Polonsky, William H
Henry, Robert R
author_facet Polonsky, William H
Henry, Robert R
author_sort Polonsky, William H
collection PubMed
description At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence. Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes. Poor medication adherence is linked to key nonpatient factors (eg, lack of integrated care in many health care systems and clinical inertia among health care professionals), patient demographic factors (eg, young age, low education level, and low income level), critical patient beliefs about their medications (eg, perceived treatment inefficacy), and perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia). Specific barriers to medication adherence in T2D, especially those that are potentially modifiable, need to be more clearly identified; strategies that target poor adherence should focus on reducing medication burden and addressing negative medication beliefs of patients. Solutions to these problems would require behavioral innovations as well as new methods and modes of drug delivery.
format Online
Article
Text
id pubmed-4966497
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49664972016-08-12 Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors Polonsky, William H Henry, Robert R Patient Prefer Adherence Review At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence. Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes. Poor medication adherence is linked to key nonpatient factors (eg, lack of integrated care in many health care systems and clinical inertia among health care professionals), patient demographic factors (eg, young age, low education level, and low income level), critical patient beliefs about their medications (eg, perceived treatment inefficacy), and perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia). Specific barriers to medication adherence in T2D, especially those that are potentially modifiable, need to be more clearly identified; strategies that target poor adherence should focus on reducing medication burden and addressing negative medication beliefs of patients. Solutions to these problems would require behavioral innovations as well as new methods and modes of drug delivery. Dove Medical Press 2016-07-22 /pmc/articles/PMC4966497/ /pubmed/27524885 http://dx.doi.org/10.2147/PPA.S106821 Text en © 2016 Polonsky and Henry. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Polonsky, William H
Henry, Robert R
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
title Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
title_full Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
title_fullStr Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
title_full_unstemmed Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
title_short Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
title_sort poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966497/
https://www.ncbi.nlm.nih.gov/pubmed/27524885
http://dx.doi.org/10.2147/PPA.S106821
work_keys_str_mv AT polonskywilliamh poormedicationadherenceintype2diabetesrecognizingthescopeoftheproblemanditskeycontributors
AT henryrobertr poormedicationadherenceintype2diabetesrecognizingthescopeoftheproblemanditskeycontributors